Abstract
The OPG/RANKL system in primary cultures of human osteoblasts has been studied by different authors. However, very few studies have been performed on gene expression of RANKL and OPG at different stages of maturation on human osteoblast cultures. The effect of 17-β-estradiol and 1,25dihydroxyvitamin D3 on the OPG/RANKL system is not known during the different states of cellular maturation. In this work we quantified OPG and RANKL protein levels (ELISA) and the mRNA of OPG, RANKL, collagen type I, alkaline phosphatase, and osteocalcin (semi-quantitative RT-PCR) in human osteoblasts. We analyzed these in basal conditions and after incubation with 17-β-estradiol and 1,25dihydroxyvitamin D3 in the first and second phases. We found that OPG secretion and expression levels increased throughout cellular growth. RANKL proteins were detected only in the first stage, and the expression increased throughout the first phase. Thus, the RANKL/OPG ratio was higher in immature osteoblasts than in mature osteoblasts. The evolution of RANKL gene expression was related to collagen I and alkaline phosphatase, while OPG was related to osteocalcin. We observed no modifications after estradiol and 1,25dihydroxyvitamin D3 treatment. Our results suggest that the OB is a positive stimulator at precocious stages of differentiation on osteoclastogenic modulates.
Key words
human osteoblast culture - 17-β-estradiol - 1,25dihydroxyvitamin D3 - osteoporosis - osteoarthritis
References
-
1
Roux S, Orcel P.
Bone loss. Factors that regulate osteoclast differentiation: an update.
Arthritis Res.
2000;
2
451-456
-
2
Manolagas SC, Jilka RL.
Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.
N Engl J Med.
1995;
332
305-311
-
3
Khosla S.
Minireview: the OPG/RANKL/RANK system.
Endocrinology.
2001;
142
5050-5055
-
4
Kaji H, Kanatani M, Sugimoto T, Chihara K.
Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Horm Metab Res.
2005;
37
589-592
-
5
Shirai Y, Yoshimura Y, Yawaka Y, Hasegawa T, Kikuiri T, Takeyama S, Matsumoto A, Oguchi H.
Effect of extracellular calcium concentrations on osteoclast differentiation in vitro.
Biochem Biophys Res Commun.
1999;
265
484-488
-
6
Deyama Y, Takeyama S, Koshikawa M, Shirai Y, Yoshimura Y, Nishikata M, Suzuki K, Matsumoto A.
Osteoblast maturation suppressed osteoclastogenesis in coculture with bone marrow cells.
Biochem Biophys Res Commun.
2000;
274
249-254
-
7
Thomas GP, Baker SUK, Eisman JA, Gardiner EM.
Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts.
J Endocrinol.
2001;
170
451-460
-
8 Stein GS, Lian JB. Molecular mechanisms mediating developmental and hormone-regulated expression of genes in osteoblasts: integrated relantionship of cell growth and differentiation. In: Noda M, ed. Cellular and molecular biology of bone. Tokyo: Academic Press 1993: 47-95
-
9
Siggelkow H, Rebenstorff K, Kurre W, Niedhart Ch, Engel I, Schilz H, Atkinson M, Hüfner M.
Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation.
J Cell Biochem.
1999;
75
22-35
-
10
Ishida H, Bellows CG, Aubin JE, Heersche JN.
Characterization of the 1,25-(OH)2D3-induced inhibition of bone nodule formation in long-term cultures of fetal rat calvaria cells.
Endocrinology.
1993;
132
61-66
-
11
Siggelkow H, Schulz H, Kaesler S, Benzler K, Atkinson MJ, Hüfner M.
1,25 dihydroxyvitamin-D3 attenuates the confluencedependent differences in the osteoblast characteristic proteins alkaline phosphatase, procollagen I peptide, and osteocalcin.
Calcif Tissue Int.
1999;
64
414-421
-
12
Bord S, Ireland DC, Beavan SR, Compston JE.
The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts.
Bone.
2003;
32
136-141
-
13
Pascher E, Perniok A, Becker A, Feldkamp J.
Effect of 1alpha,25(OH)2-vitamin D3 on TNF alpha-mediated apoptosis of human primary osteoblast-like cells in vitro.
Horm Metab Res.
1999;
31
653-656
-
14
Spreafico A, Frediani B, Capperucci C, Chellini F, Paffetti A, D'Ambrosio C, Bernardini G, Mini R, Collodel G, Scaloni A, Marcolongo R, Santucci A.
A proteomic study on human osteoblastic cells proliferation and differentiation.
Proteomics.
2006;
6
3520-3532
-
15
Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS.
Osteoblast proliferation and maturation by bisphosphonates.
Biomaterials.
2004;
25
4105-4115
-
16
Martinez ME, del Campo MT, Medina S, Sanchez M, Sanchez-Cabezudo MJ, Esbrit P, Martinez P, Moreno I, Rodrigo A, Garces MV, Munuera L.
Influence of skeletal site of origin and donor age on osteoblastic cell growth and differentiation.
Calcif Tissue Int.
1999;
64
280-286
-
17
Owen TA, Aronow MS, Barone LM, Bettencourt B, Stein GS, Lian JB.
Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures.
Endocrinology.
1991;
128
1496-1504
-
18
Gerstenfeld LC, Chipman SD, Glowacki J, Lian JB.
Expression of differentiated function by mineralizing cultures of chicken osteoblasts.
Dev Biol.
1987;
122
49-60
-
19
Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, Hampson G.
Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
J Endocrinol.
2003;
177
423-433
-
20
Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL.
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
J Cell Biol.
1999;
145
527-538
-
21
Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A.
Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstandin rheumatoid arthritis and osteoarthritis.
Rheumatol Int.
2005;
26
63-69
-
22
Viereck V, Grundker C, Blaschke S, Siggelkow H, Emons G, Hofbauer LC.
Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts.
J Cell Biochem.
2002;
84
725-735
-
23
Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL.
The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.
Endocrinology.
2000;
141
4768-4776
-
24
Chen Q, Kaji H, Kanatani M, Sugimoto T, Chihara K.
Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells.
Horm Metab Res.
2004;
36
674-678
-
25
Baldock PA, Thomas GP, Hodge JM, Baker SU, Dressel U, O'Loughlin PD, Nicholson GC, Briffa KH, Eisman JA, Gardiner EM.
Vitamin d action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast.
J Bone Miner Res.
2006;
21
1618-1626
-
26
Picotto G.
Rapid effects of calciotropic hormones on female rat enterocytes: combined actions of 1,25(OH)2-vitamin D3, PTH and 17beta-estradiol on intracellular Ca2+regulation.
Horm Metab Res.
2001;
33
733-738
-
27
Chen FP, Lee N, Wang KC, Soong YK, Huang KE.
Effect of estrogen and 1alpha,25(OH)2- vitamin D3 on the activity and growth of human primary osteoblast-like cells in vitro.
Fertil Steril.
2002;
77
1038-1043
-
28
Bellido T, Girasole G, Passeri G, Yu XP, Mocharla H, Jilka RL, Notides A, Manolagas SC.
Demonstration of estrogen and vitamin D receptors in bone marrow-derived stromal cells: up-regulation of the estrogen receptor by 1,25-dihydroxyvitamin-D3.
Endocrinology.
1993;
133
553-562
-
29
Vertino AM, Bula CM, Chen JR, Almeida M, Han L, Bellido T, Kousteni S, Norman AW, Manolagas SC.
Nongenotropic, anti-apoptotic signaling of 1alpha,25(OH)2-vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes. Mediation by Src, phosphatidylinositol 3-, and JNK kinases.
J Biol Chem.
2005;
280
14130-14137
-
30
Arts J, Kuiper GG, Janssen JM, Gustafsson JA, Löwik CW, Pols HA, Leeuwen JP van.
Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells.
Endocrinology.
1997;
138
5067-5070
-
31
Bord S, Horner A, Beavan S, Compston J.
Estrogen receptors alpha and beta are differentially expressed in developing human bone.
J Clin Endocrinol Metab.
2001;
86
2309-2314
-
32
Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C.
Androgens and bone.
Endocr Rev.
2004;
25
389-425
-
33
Parfitt AM.
Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone.
J Cell Biochem.
1994;
55
273-286
Correspondence
M. Giner
Bone Metabolism Unit
Internal Medicine
University Hospital
Av. Dr. Fedriani s/n
41018 Seville
Spain
Phone: +34/954/55 66 16 17
Fax: +34/954/55 66 17
Email: merce_giner@yahoo.es
